Literature DB >> 8077664

Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae.

G S Hui1, W L Gosnell, S E Case, C Hashiro, C Nikaido, A Hashimoto, D C Kaslow.   

Abstract

The immunogenicity of the C-terminal 19-kDa fragment of Plasmodium falciparum MSP1 expressed in yeast as a nonfusion product, YMSP1(19), was studied. Immunization with YMSP1(19) in rabbits induced high titers of Abs specific for native conformational epitopes on parasite MSP1. In mice, immunogenicity was dependent on the mouse strain and the adjuvant formulation. This suggests that different adjuvants may alter the immunogenicity of MSP1(19) in a genetically diverse population. Although YMSP1(19) induced anti-MSP1 Abs, they did not inhibit in vitro parasite growth. This contrasts with the strong inhibitory activities of Abs produced against a recombinant MSP1(42) (BVp42), which contains the entire MSP1(19) coding sequence. Further analyses showed that YMSP1(19) was the target of the inhibitory, anti-BVp42 Abs because YMSP1(19) could completely block binding of anti-BVp42 Abs to parasite MSP1 or BVp42. Moreover, depletion of YMSP1(19)-specific Abs completely abolished the parasite inhibitory activities of anti-BVp42 sera. Anti-YMSP1(19) sera did not block the inhibitory activities of anti-BVp42 sera, suggesting that inhibitory epitopes were not in close structural proximity with noninhibitory epitopes. The finding that YMSP1(19) possessed inhibitory epitopes but induced anti-MSP1 Abs that were not inhibitory suggests that although the T-epitope(s) produced by immunization with YMSP1(19) could provide help for Ab production, it did not induce an effective inhibitory Ab response. We hypothesize that the nature/specificity of T helper epitopes on MSP1 may be crucial in efficient induction of biologically relevant and/or protective Abs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077664

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.

Authors:  Kae Pusic; Hengyi Xu; Andrew Stridiron; Zoraida Aguilar; Andrew Wang; George Hui
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

4.  Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

Authors:  Mark Nagata; Teri Wong; David Clements; George Hui
Journal:  Exp Parasitol       Date:  2006-11-21       Impact factor: 2.011

5.  Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1.

Authors:  Y P Shi; U Sayed; S H Qari; J M Roberts; V Udhayakumar; A J Oloo; W A Hawley; D C Kaslow; B L Nahlen; A A Lal
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

6.  Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

Authors:  A W Stowers; V Cioce; R L Shimp; M Lawson; G Hui; O Muratova; D C Kaslow; R Robinson; C A Long; L H Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

7.  Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.

Authors:  Danielle I Stanisic; Laura B Martin; Xue Q Liu; David Jackson; Juan Cooper; Michael F Good
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

8.  Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.

Authors:  G S Hui; C Nikaido; C Hashiro; D C Kaslow; W E Collins
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

9.  Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.

Authors:  Kae Pusic; Zoraida Aguilar; Jaclyn McLoughlin; Sophie Kobuch; Hong Xu; Mazie Tsang; Andrew Wang; George Hui
Journal:  FASEB J       Date:  2012-11-29       Impact factor: 5.191

10.  Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Authors:  Nekoye Otsyula; Evelina Angov; Elke Bergmann-Leitner; Margaret Koech; Farhat Khan; Jason Bennett; Lucas Otieno; James Cummings; Ben Andagalu; Donna Tosh; John Waitumbi; Nancy Richie; Meng Shi; Lori Miller; Walter Otieno; Godfrey Allan Otieno; Lisa Ware; Brent House; Olivier Godeaux; Marie-Claude Dubois; Bernhards Ogutu; W Ripley Ballou; Lorraine Soisson; Carter Diggs; Joe Cohen; Mark Polhemus; D Gray Heppner; Christian F Ockenhouse; Michele D Spring
Journal:  Malar J       Date:  2013-01-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.